Vanguard Group
SER icon

Vanguard Group’s Serina Therapeutics SER Stock Holding History

Vanguard Group’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$344K Hold
180,013
– – ﹤0.01% 4014
2025
Q3 		$965K Buy
180,013
+29,390
+20% +$156K ﹤0.01% 3798
2025
Q2 		$928K Buy
150,623
+85,290
+131% +$485K ﹤0.01% 3764
2025
Q1 		$370K Buy
65,333
+3,260
+5% +$15.4K ﹤0.01% 3949
2024
Q4 		$311K Buy
62,073
+17,573
+39% +$104K ﹤0.01% 4040
2024
Q3 		$298K Buy
44,500
+22,368
+101% +$178K ﹤0.01% 4078
2024
Q2 		$212K Buy
22,132
+2,181
+11% +$21.5K ﹤0.01% 4160
2024
Q1 		$269K Sell
19,951
-2
-0% -$28 ﹤0.01% 4127
2023
Q4 		$270K Buy
19,953
+95
+0.5% +$1.75K ﹤0.01% 4176
2023
Q3 		$475K Hold
19,858
– – ﹤0.01% 4064
2023
Q2 		$624K Hold
19,858
– – ﹤0.01% 4058
2023
Q1 		$463K Hold
19,858
– – ﹤0.01% 4142
2022
Q4 		$385K Sell
19,858
-41
-0.2% -$864 ﹤0.01% 4171
2022
Q3 		$393K Hold
19,899
– – ﹤0.01% 4281
2022
Q2 		$403K Sell
19,899
-33
-0.2% -$891 ﹤0.01% 4338
2022
Q1 		$599K Buy
19,932
+5
+0% +$142 ﹤0.01% 4352
2021
Q4 		$764K Hold
19,927
– – ﹤0.01% 4337
2021
Q3 		$659K Buy
19,927
+255
+1% +$10.7K ﹤0.01% 4334
2021
Q2 		$1.07M Hold
19,672
– – ﹤0.01% 4138
2021
Q1 		$1.12M Buy
19,672
+1,284
+7% +$89.8K ﹤0.01% 3985
2020
Q4 		$983K Buy
18,388
+310
+2% +$17.9K ﹤0.01% 3832
2020
Q3 		$515K Sell
18,078
-291
-2% -$10.4K ﹤0.01% 3808
2020
Q2 		$611K Sell
18,369
-2,364
-11% -$69.6K ﹤0.01% 3724
2020
Q1 		$678K Sell
20,733
-43
-0.2% -$2.02K ﹤0.01% 3601
2019
Q4 		$1.33M Sell
20,776
-81
-0.4% -$4.38K ﹤0.01% 3559
2019
Q3 		$1.44M Buy
20,857
+880
+4% +$83.5K ﹤0.01% 3551
2019
Q2 		$2.58M Buy
19,977
+5,603
+39% +$759K ﹤0.01% 3398
2019
Q1 		$2.05M Buy
14,374
+918
+7% +$134K ﹤0.01% 3442
2018
Q4 		$1.42M Buy
+13,456
New +$1.71M ﹤0.01% 3466

Other funds holding SER

WA
Waverly Advisors Birmingham, Alabama $13.4B AUM 18.56% 1-Year Est. Return
BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LW
Linscomb Wealth Houston, Texas $2.31B AUM 28.23% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group's SER Position: Q4 2025 in Review

Vanguard Group held its Serina Therapeutics (SER) position steady in Q4 2025 at 180,013 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #4014.

Vanguard Group first reported a position in SER in Q4 2018 and has held it in 29 quarters since. The position peaked at $2.58M in Q2 2019. 22 funds tracked by Wall St. Rank hold SER as of Q4 2025.

  • Vanguard Group held 180,013 shares of Serina Therapeutics worth $344K as of Q4 2025.
  • Vanguard Group left its Serina Therapeutics share count unchanged in Q4 2025.
  • Serina Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4014 holding.
  • Vanguard Group first reported a position in Serina Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • Vanguard Group's Serina Therapeutics position peaked at $2.58M in Q2 2019.
  • 22 funds tracked by Wall St. Rank held Serina Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.